Navigation Links
Ace Biosciences, Ace393, the World's First Commercial Vaccine for,Travellers' Diarrhoea Caused by Campylobacter Successfully,Completes Phase I Clinical Trials

Ace Biosciences, Ace393, the World's First Commercial Vaccine for Travellers' Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials

Trial confirms good safety profile and strong immunogenicity

ODENSE, Denmark, March 28, 2007 -ACE BioSciences A/S, the infectious diseases company is pleased to announce the successful completion of Phase I clinical trials with its lead product, ACE393, the world's first commercial vaccine for Travellers' Diarrhoea (TD) caused by Campylobacter infection.

ACE393 is an injectable vaccine designed to combat the bacterium Campylobacter jejuni, one of the greatest causes of bacterial diarrhoeal infections in the developed world. The two stage, double blind, randomised, placebo-controlled trial confirmed that the vaccine was very well tolerated and that the strongest immune response was stimulated by the highest dose when administered in two doses either two or three weeks apart, with 100% of subjects responding. Adverse reactions were transient local site reaction and headaches in some subjects.

Dr Philippe Reboud, (Mediscis Phase I clinical unit) the study_s Principal Investigator commented "These are very satisfying results. The study clearly confirms the vaccine's safety and tolerability. Furthermore, at the 250µg dose, ACE393 stimulates a four fold increase in IgG antibody titre in all subjects, indicating strong immunogenicity (ability to stimulate an immune response). In the past it has proved too challenging to develop an effective vaccine against Campylobacter infection and Travellers' Diarrhoea has been difficult to prevent, leading to the incidence of serious long-term post infection complications such as Guillain Barre Syndrome and reactive arthritis in a few patients. However, thanks to the innovative approach taken by ACE BioSciences, this looks set to change."

Ms Ingelise Saunders, ACE BioSciences, C
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
2. Abbott Announces Positive Six-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
5. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
6. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
7. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
8. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
9. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
10. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
11. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
Post Your Comments:
(Date:1/15/2014)... , Jan. 15, 2014 As health officials across ... virus, select Meijer pharmacies in Michigan ... to eligible patients, enabling Meijer pharmacists to administer tests and, ... set by a physician participating in the study. ...
(Date:1/15/2014)... OAKS, Calif. , Jan. 15, 2014 ... Amgen (NASDAQ: AMGN ) announced today ... jointly discover and validate new therapeutic targets and ... a chronic disorder that affects millions worldwide. The ...
(Date:1/15/2014)...  Manufacturers, suppliers and distributors of innovative medical-related products ... most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the Medical ... most litigious industry sectors of cases involving IP ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Intellectual Property Insurance for Medical-related Products and Services 2
... Calif., Jan. 6, 2011 Genesis ... ), a biotechnology company developing targeted cancer therapies, announces that ... Biotech Showcase™ 2011 conference on Wednesday, January 12, 2011, at ... the Parc 55 Wyndham San Francisco – Union Square. ...
... Jan. 5, 2011 WebMD Health Corp. (Nasdaq: ... million of Convertible Notes due 2018 in a private placement. ... proposed offering an option to purchase up to an additional ... being offered only to qualified institutional buyers pursuant to Rule ...
Cached Medicine Technology:Genesis Biopharma to Present at 2011 Biotech Showcase Conference 2WebMD Announces Proposed Offering of Convertible Notes 2
(Date:4/17/2014)... military personnel who served in Iraq and Afghanistan ... injury (TBI) were compared to military personnel without ... Differences in measures of overall disability, cognitive function, ... are reported in an article in Journal ... Ann Liebert, Inc., publishers. The article is available ...
(Date:4/17/2014)... cause of neuronal death in Parkinson,s disease is still ... be mistaken for foreign invaders and killed by the ... diseases like type I diabetes, celiac disease, and multiple ... April 16, 2014, in Nature Communications . , ... Parkinson,s disease; but if true, it could lead to ...
(Date:4/17/2014)... of Medicine (BUSM) have discovered that the anti-seizure ... model. The findings, reported in the American ... lead to more effective treatments for alcoholism. , ... leading causes of illness and death in the ... limiting the productivity of workers and necessitating huge ...
(Date:4/17/2014)... has the potential to ward off depression among retirees, ... published online in The Journals of Gerontology, ... In the article " Internet Use and Depression Among ... Analysis ," the authors report that Internet use reduced ... among their study sample. , Late-life depression affects ...
(Date:4/17/2014)... ribbon representing a disease. A pink ribbon is well known ... think of with lung cancer?, Although white has been identified ... black may be the only one they think fits., A ... smokers between the ages of 51 to 79 years old, ... these patients, the emotional toll it can have and how ...
Breaking Medicine News(10 mins):Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Is Parkinson's an autoimmune disease? 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Internet use may cut retirees' depression 2Health News:Unraveling the 'black ribbon' around lung cancer 2
... of intestinal stem cells that may hold clues to the ... reported March 30 in the journal Cell , appears ... recent discovery of intestinal stem cells that multiply rapidly ... as a "brake" on cell growth and proliferation. , The ...
... renal cell carcinoma, the second most common kidney cancer subtype, ... after surgery. Those are the key findings of a multi-centre ... of the urology journal BJUI . ... to 15% of kidney cancer patients, the small number of ...
... R.I. Rhode Island Hospital physicians identified ... that required endoscopic or surgical removal. The paper calls attention ... aware of this potential danger. It is published in the ... online in advance of print. David Grand, M.D., a ...
... , WEDNESDAY, March 28 (HealthDay News) -- In ... the popular antidepressant Celexa can cause potentially fatal abnormal ... issued new dosing and use recommendations. Last August, ... than 40 milligrams a day can cause changes in ...
... radiation therapy (IMRT) instead of standard whole breast irradiation ... toxicities, according to a study in Practical Radiation ... journal of the American Society for Radiation Oncology (ASTRO)., ... effective breast cancer treatment that also reduces the incidence ...
... (HealthDay News) -- The common cold appears to increase ... makes them more sensitive, which triggers coughing, wheezing and ... are especially vulnerable to this virus-induced coughing, said the ... are known as transient receptor potential (TRP) receptors. ...
Cached Medicine News:Health News:Newly identified stem cells may hold clues to colon cancer 2Health News:Kidney cancer subtype study finds low recurrence and cancer death rates 2Health News:Rhode Island Hospital study identifies the danger of grill brushes 2Health News:FDA Adds More Warnings to Antidepressant's Label 2Health News:IMRT reduces risk of side effects in breast cancer patients 2Health News:Research Shows How Colds Lead to Coughing, Wheezing 2
Boston Multivision design is manufactured in Boston ES material for early presbyope patients. Boston Multivision lens provides crisp, clear vision at near, intermediate, and far distances and excelle...
Ophthalmic surgery stretcher. Designed for exceptional surgeon access, ideal for either superior or temporal approach....
... Reliance mobile surgical stretcher. M-701 ... of 24 in. to 32 in., ... You may specify a high range, ... A 4 in. pad can be ...
... Visionblue is a staining solution for ... required for performing a safe phaco-emulsification ... lens capsule may result in an ... risk of radial capsule tears and ...
Medicine Products: